Alnylam Pharma (ALNY) AI Stock Analysis

• Market Cap: $59.14B
• Dividend Yield: N/A
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 5.01%
• EPS Growth: -330.09%
• Country: US
• Employees: 2,230
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 131,079,010
• 10 Day Avg. Volume: 1,244,529
• 30 Day Avg. Volume: 1,245,435
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 17.25
• Enterprise Value/Gross Profit: 20.63
• Enterprise Value/Ebitda: -248.52
• 1Y Price Target: $432.64
• Price Target Upside: -4.35% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 28

• Rating: 60 Neutral
• Price Target: $479.00 ▲(5.90% Upside)

Alnylam Pharma's overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.

Positive Factors

Market Expansion

ALNY received regulatory approval in Brazil, Europe, the UK, and Japan for its therapies, expanding its market reach.

Product Launch

The U.S. approval and launch of AMVUTTRA in ATTR-CM led to a sharp inflection in sales, prompting a $600M upward revision to full-year guidance.

Negative Factors

Profit Margins

A 30% royalty payment to Sanofi affects Alnylam's margins, making Amvuttra less profitable.

Valuation Concerns

Alnylam's valuation is stretched, which still raises concerns despite positive market performance.

Alnylam Pharma Business Overview & Revenue Model

Company Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Alnylam Pharmaceuticals generates revenue primarily through the sale of its approved therapies, most notably Onpattro. The company also earns income through collaborations and partnerships with other pharmaceutical companies, which may include upfront payments, milestone payments based on development progress, and royalties on product sales. Notable partnerships with companies like Sanofi and Regeneron have further enhanced its revenue streams, allowing for shared development costs and increased market reach. Additionally, Alnylam may receive government grants and funding for research projects, contributing to its earnings.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma faces significant financial challenges with negative net profit margins, high leverage, and negative cash flows, despite a strong gross profit margin. The company's financial stability is at risk due to its high debt levels and ongoing losses.

Income Statement

Alnylam Pharma shows a modest revenue growth rate of 4.85% in the TTM, but profitability remains a concern with negative net profit and EBIT margins. The gross profit margin is relatively strong at 58.02%, indicating efficient production, but the company struggles to convert this into net profits.

Balance Sheet

The company has a high debt-to-equity ratio of 5.18 in the TTM, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting ongoing losses. The equity ratio is low, suggesting limited equity financing relative to total assets.

Cash Flow

Alnylam Pharma's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow to net income ratio is positive, suggesting some ability to cover net losses, but overall cash flow growth is negative, indicating potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.46B	2.25B	1.83B	1.04B	844.29M	492.85M
Gross Profit	2.06B	1.92B	1.52B	868.60M	704.14M	414.80M
EBITDA	-170.93M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
Net Income	-319.09M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet
Total Assets	4.57B	4.24B	3.83B	3.55B	3.64B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.86B	2.69B	2.44B	2.19B	2.44B	1.87B
Total Debt	1.30B	1.30B	1.31B	1.32B	997.59M	521.19M
Total Liabilities	4.32B	4.17B	4.05B	3.70B	3.06B	2.39B
Stockholders Equity	250.59M	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow
Free Cash Flow	-52.09M	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
Operating Cash Flow	-15.54M	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
Investing Cash Flow	-110.77M	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
Financing Cash Flow	231.59M	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 452.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Positive. The current price of 452.33 is above the 20-day moving average (MA) of 441.41, above the 50-day MA of 371.44, and above the 200-day MA of 287.87, indicating a bullish trend. The MACD of 25.46 indicates Positive momentum. The RSI at 69.41 is Neutral, neither overbought nor oversold. The STOCH value of 47.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALNY.

Alnylam Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	82 Outperform	$15.14B	12.27	26.08%	―	23.25%	64.46%
INCY	80 Outperform	$16.40B	19.10	24.30%	―	18.87%	1088.27%
VRTX	75 Outperform	$99.27B	27.81	22.77%	―	10.38%	―
ARGX	74 Outperform	$42.66B	33.26	24.75%	―	89.58%	―
ALNY	60 Neutral	$59.14B	―	-257.82%	―	5.01%	-330.09%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
BNTX	49 Neutral	$25.19B	―	-1.81%	―	7.51%	30.53%

Alnylam Pharma Corporate Events

Alnylam Pharma Appoints New Chief R&D Officer

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.